

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Olumiant (baricitinib) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorization: 12 months

## **Instructions:**

This form is used by Kaiser Permanente and/or participating providers for coverage of **Olumiant (baricitinib)**. Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: <u>1-866-331-2104</u>]. If you have any questions or concerns, please call <u>1-866-331-2103</u>. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: <a href="http://pithelp.appl.kp.org/MAS/formulary.html">http://pithelp.appl.kp.org/MAS/formulary.html</a>** 

	1 – Patient Information			
Patient Name:	Kaiser Medical ID#:	Date of Birth:		
2 – Provider Information				
Provider Name:	Specialty:	Provider NPI:		
Provider Address:				
Provider Phone #:	Provider Fax #:			
Please check the boxes that apply:  □ Initial Request □ Continuation of Therapy F	Request			
3 – Pharmacy Information				
Pharmacy Name:	Pharmacy NPI:			
Pharmacy Phone #	Pharmacy Fax #:			
	4 – Drug Therapy Requested			
Drug 1: Name/Strength/Formulation:				
Sig:				
Drug 2: Name/Strength/Formulation:				
Sig:				

## 5- Diagnosis/Clinical Criteria

1.		the member have diagnosis of one of the following? <b>AND</b> umatoid Arthritis (RA)		
	□ Othe	er:		
2.	Was there therapeutic failure on oral methotrexate? <b>AND</b> □ No □ Yes			
3.	Was th  ☐ No ☐	nere therapeutic failure to one of the preferred agents? (e.g. Er Yes	nbrel, Humira) <b>AND</b>	
4.		is being used for <u>Rheumatoid arthritis</u> (RA): Is the patient ≥ 18 years old? <b>AND</b> □ No □ Yes		
	b.	Is this being used in combination with other JAK inhibitors, bi (DMARDs), or with potent immunosuppressants, such as azat recommended) <b>AND</b> □ No □ Yes		
	C.	Has the patient had an inadequate response to one or more therapies?  □ No □ Yes	tumor necrosis factor (TNF) antagonist	
6 – Provider Sign-Off				
dditio	onal Info	ormation – Please provide any additional information that sho	ould be taken into consideration.	
l cert	ify that t	the information provided is accurate. Supporting documentation is	available for State audits.	
	ider Sigi		Date:	
inform	mation is p	is document contains confidential information, including protected health information brivate and legally protected by law, including HIPAA. If you are not the intended recip taking of any action in reliance on the contents of this telecopied information is strictly	ient, you are hereby notified that any disclosure, copying,	

intended for receipt by your facility